FOREWORD AND INTRODUCTION
This issue of the Drug Information Journal contains the papers from the fourth international meeting dealing with the causality assessments of suspected adverse drug reactions. The first international meeting on this subject (Morges, Switzerland, September 1981) recognized the great diversity of approaches to assessing causality of adverse drug reactions which had been ongoing for almost ten years stemming from the work of hey, Karsh, and Lasagna. A major product of this conference was a book of the proceedings which provided a useful overview of all of the different methods of causality assessment as well as the wide range of issues that needed to be addressed before any sense of international consensus could be obtained. Despite diverse approaches, there was some feeling at the meeting that the possibility of consensus, at least on some issues such as the critical data elements, was needed for assessments.
Two meetings followed this initial meeting which signified the commitment of those working in the area to continued dialogue, and efforts to define better methods and areas of consensus. The first was held in Washington, DC and was sponsored by the Drug Information Association (DIA). This meeting had as its specific purpose the application of a number of the different methods to standard cases with the idea of broadening the audience's understanding of both the methods and the controversial issues by workshop participation. An additional purpose was to bring in others active in the field of thinking about causality in general (but not necessarily regarding adverse reaction) in an effort to provide a fresh look at the subject. Similar efforts were reflected on the European side of the Atlantic at a meeting in Paris shortly thereafter, again providing a thread of continuity stemming from the Morges meeting.
One of the major results of these 1982 meetings was to stimulate the possibility of a new and different approach toward the problem of causality assessment of adverse drug reactions. This was originally proposed by Dr David Lane, a theoretical statistician who had been invited originally to the Washington DIA meeting to provide the "fresh look." As a result of his interaction with investigators in this area, an ongoing working group began to elaborate this approach based on the laws of probability. This effort was stimulated by research funding from the Drug Information Association and subsequently the American Medical Association. This workshop represents one of the requirements of the funding, that is, to present the work developed during the funding period at a public forum for comment. Accordingly, the content of this program consists greatly of the results of this effort.
However, this program and accordingly this monograph, had also as its purpose to provide another benchmark in the ongoing dialogue of those interested in the entire area of causality assessment. Thus, papers contained herein include views of those various parties which must address the issue of causation of adverse reactionsthe legal community, the pharmaceutical manufacturers, the academic community, as well as those working directly on a dayto-day basis with adverse drug reaction assessment and use of data.
The better part of this monograph is devoted to the actual demonstration of a proposed new method, which is based on use of Bayes theorem and a probability-based approach to adverse drug reaction assessment. This method is in its beginning stages but offers a number of advantages illustrated by.a number of the introductory papers by Drs Lane, Hutchinson, Naranjo, and Kramer. The need for such a probabilistic approach is outlined in Dr Jones' paper relating to prespectives in the epidemiologic arena. The application of this method is elaborated in considerable detail as it is applied to several cases, both those presented at the workshop as well as an extra case subsequently developed.
The symposium and the monograph are also complemented by comments from a number of noted researchers in the field of adverse reactions and causality, and finally highlighted by yet another outside observer to this process, an expert in artificial intelligence or expert systems. As outlined in this paper, he examines this particular approach and outlines the possible ways in which it could be used in more practical ways joining the method with developing computer methods.
Finally, as a service to the reader and those following the progress of the work in the field of causality assessment of adverse reactions, we have included an up-dated list of selected references for those who wish to delve further into the field. In conclusion, this monograph represents yet another benchmark in the ongoing progress toward truly understanding adverse drug reactions and assessing their causal association with drugs. The hope is that the new method developed provides at the very minimum a map for delineating our areas of ignorance and pointing various ways in which we can make progress in the field, not only of causality, but also of understanding adverse drug induced disease. 
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